Sesen Bio announced the expansion of its leadership team with the appointment of experienced industry leaders to several key roles: Mark R. Sullivan to General Counsel and Corporate Secretary, Erin Clark to Vice President, Corporate Strategy and Investor Relations, Monica Forbes to Vice President, Finance and Omar Rifi to Vice President, Business Development and Alliance Management. Mark R. Sullivan has more than 20 years of legal experience in the life sciences and healthcare industries. Mr. Sullivan joined Sesen Bio in April 2018 as the acting general counsel. Prior to joining Sesen, he provided outsourced in-house counsel services to a variety of companies including Sandoz Inc. and Bayer Healthcare. Erin Clark brings extensive leadership experience in strategy and commercialization of late-stage life science companies. Ms. Clark joined Sesen Bio in January 2019 as the executive director of strategy planning and investor relations. Prior to joining Sesen, Ms. Clark held various leadership roles at Trevena, Inc. and Orexigen Therapeutics, Inc., where she helped drive commercialization and realization of external value drivers for lead assets in development and approved marketed products. Monica Forbes brings more than 20 years of financial leadership experience to Sesen Bio, including prior experience leading the finance and administrative functions of late and commercial-stage public and private life science companies. Ms. Forbes most recently served as the chief financial officer of Nalpropion Pharmaceuticals where she led the integration of a newly acquired asset and supporting commercial team. Omar Rifiis a seasoned leader in the pharmaceutical industry with extensive global commercial experience. Most recently, Mr. Rifi served as vice president, global alliances at Nalproprion Pharmaceuticals where he led revenue maximization efforts within launched territories outside of the United States and led the registration process and launch readiness in key countries across Latin America and Asia Pacific.